Table 1.
Baseline patient characteristics after propensity score matching
| Characteristics | Overall (N = 248) | CT-P13 (n = 124) | Reference infliximab (n = 124) | p value |
|---|---|---|---|---|
| Age at start, years | 39.2 ± 13.4 | 38.6 ± 13.3 | 39.7 ± 13.5 | 0.50 |
| Disease duration, years | 4.3 ± 5.3 | 4.2 ± 5.2 | 4.3 ± 5.4 | 0.94 |
| Male, n (%) | 184 (74) | 94 (76) | 90 (73) | 0.60 |
| Smoking status, n (%) | 0.74 | |||
| Ex-smoker | 51 (21) | 26 (21) | 25 (20) | |
| Current smoker | 71 (29) | 33 (27) | 38 (31) | |
| Never | 126 (51) | 65 (52) | 61 (49) | |
| BMI, kg/m2 | 23.6 ± 3.2 | 23.8 ± 3.2 | 23.3 ± 3.2 | 0.17 |
| Swollen joint counts | 0.6 ± 1.9 | 0.8 ± 2.4 | 0.4 ± 1.0 | 0.11 |
| Tender joint counts | 0.8 ± 2.4 | 1.1 ± 3.1 | 0.5 ± 1.2 | 0.07 |
| BASDAI | 5.5 ± 1.9 | 5.5 ± 1.9 | 5.5 ± 2.0 | 0.50 |
| Patient’s GA | 5.8 ± 2.2 | 5.8 ± 2.1 | 5.8 ± 2.2 | 0.76 |
| ASDAS-ESR | 3.5 ± 1.1 | 3.4 ± 1.0 | 3.5 ± 1.1 | 0.51 |
| ASDAS-CRP | 3.3 ± 1.1 | 3.4 ± 1.0 | 3.3 ± 1.2 | 0.21 |
| ESR, mm/h, n (%) | ||||
| Normal | 84 (34) | 44 (36) | 40 (33) | 0.59 |
| ESR | 35.7 ± 30.8 | 34.9 ± 31.9 | 36.4 ± 29.9 | 0.71 |
| CRP, mg/dL, n (%) | ||||
| Normal | 90 (37) | 39 (32) | 51 (41) | 0.16 |
| CRP | 2.2 ± 3.2 | 2.3 ± 3.2 | 2.1 ± 3.3 | 0.47 |
| HLA-B27 status, n (%) | 0.32 | |||
| Not determined | 17 (7) | 11 (9) | 6 (5) | |
| Positive | 206 (83) | 98 (79) | 108 (87) | |
| Negative | 25 (10) | 15 (12) | 10 (8) | |
Data presented are mean (standard deviation), unless otherwise indicated
ASDAS Ankylosing Spondylitis Disease Activity Score, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BMI body mass index, CRP C-reactive protein, ESR erythrocyte sedimentation rate, GA global assessment, HLA-B27 human leukocyte antigen-B27